Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Qiagen N.V. (QGEN - Snapshot Report) attempted to expand its molecular assay portfolio used in next-generation sequencing (NGS). The effort is a part of its intention to provide an ecosystem of products and services, which increase the use of this NGS platform in clinical research and diagnostics. Accordingly, the company displayed its NGS products at the European Society of Human Genetics Conference in Paris from Jun 8–11.

In late 2012, Qiagen launched 9 GeneRead DNAseq panels, which will gradually be expanded to 20 validated gene panels. These panels are expected to offer new opportunities for targeted clinical sequencing in a growing range of indications in cancer and other diseases.

Qiagen offers 8 focused and curated NGS gene panels for different types of cancer, each covering approximately 20 different genes of interest. The company also offers a complete cancer panel, covering 124 different genes. According to Qiagen, the panels will focus on various cancers as well as new disease areas.

Moreover, Qiagen also demonstrated its cloud-based Variant Analysis software at the conference. The company had gained access to this software by acquiring Ingenuity Systems in early 2013. This system enables rapid translation of raw sequencing data into actionable results.

Viewing the substantial potential of the molecular diagnostic market globally, Qiagen is currently focusing on expanding its diagnostics products offering. The company currently derives around 50% of its total revenue from this segment, which is likely to increase with this acquisition. Qiagen has acquired several companies to expand its product portfolio, the significant ones are Ingenuity Systems, Inc. in 2013, Cellestis and Ipsogen in 2011.

As per Qiagen, faster and efficient data analysis by the Ingenuity products will enhance its prospective in the rapidly growing market of sequencing. We are encouraged by Qiagen’s focus on strategic initiatives to drive growth and profitability in the molecular diagnostics market. Its innovative tests in the genomic/esoteric arena, with a focus on the high-margin esoteric testing business, are expected to accelerate sales growth on the back of growing market demand, not only domestic but worldwide.

This is also provoking several small laboratory companies to introduce their comprehensive portfolio of genetic tests.

Major Peers in Molecular Diagnostics Space

Qiagen is facing intense competition in the molecular diagnostic space, especially from Laboratory Corp of America Holdings (LH - Analyst Report). Currently, Qiagen retains a Zacks Rank #3 (Hold). However, other stocks in the medical device sector like Haemonetics Inc. (HAE - Analyst Report) and Natus Medical Inc. (BABY - Snapshot Report), carrying a Zacks Rank #1 (Strong Buy), appear impressive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%